PolyPeptide Group AG (XSWX:PPGN) Accounts Payable: CHF65.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:PPGN PolyPeptide Group AG XSWX:PPGN
80 GF Score
Price CHF44.10
GF Value CHF34.68
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Accounts Payable?

PolyPeptide Group AG XSWX:PPGN +0.23% 80 Accounts Payable is CHF65.1 Mil as of Jun. 2026. GuruFocus rates XSWX:PPGN with a GF Score™ of 80/100 and a GF Value™ of CHF34.68 (Modestly Overvalued). The stock has 5 warning signs investors should review.

PolyPeptide Group AG's Accounts Payable for the quarter that ended in Jun. 2026 was CHF65.1 Mil.

PolyPeptide Group AG's quarterly Accounts Payable increased from Jun. 2025 (CHF63.0 Mil) to Dec. 2025 (CHF69.3 Mil) but then declined from Dec. 2025 (CHF69.3 Mil) to Jun. 2026 (CHF65.1 Mil).

PolyPeptide Group AG's annual Accounts Payable increased from Dec. 2023 (CHF57.4 Mil) to Dec. 2024 (CHF68.4 Mil) and increased from Dec. 2024 (CHF68.4 Mil) to Dec. 2025 (CHF69.3 Mil).

PolyPeptide Group AG Accounts Payable Related Terms

PolyPeptide Group AG Accounts Payable Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Accounts Payable Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 29.64 45.33 57.44 68.39 69.34

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.01 68.39 63.03 69.34 65.09
XSWX:PPGN
80GF Score
PolyPeptide Group AG XSWX:PPGN
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of CHF65.1 Mil mean?
PolyPeptide Group AG (XSWX:PPGN) has a Accounts Payable of CHF65.1 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Accounts Payable too high?
PolyPeptide Group AG's current Accounts Payable is CHF65.1 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Accounts Payable compare to ZTS and UTHR?
PolyPeptide Group AG's Accounts Payable of CHF65.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Accounts Payable is CHF65.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (XSWX:PPGN) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF34.68, compared to a current price of CHF44.10 — trading 27.2% above its estimated fair value. The current Accounts Payable is CHF65.1 Mil. PolyPeptide Group AG's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For PolyPeptide Group AG (XSWX:PPGN), the current Accounts Payable is CHF65.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF44.10 is trading 27.2% above its estimated GF Value™ of CHF34.68. GuruFocus considers PolyPeptide Group AG to be Modestly Overvalued.

Key valuation signals for XSWX:PPGN:

  • Accounts Payable: CHF65.1 Mil
  • GF Value™: CHF34.68 vs. price of CHF44.10 (27.2% above fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
80GF Score

Get the complete analysis for XSWX:PPGN

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF44.10
Price
CHF34.68
GF Value